1. Evaluation of the antiviral activity of (1'S,2'R)-9-[[1',2'-bis(hydroxymethyl)cycloprop-1'-yl]methyl]guanine (A-5021) against equine herpesvirus type 1 in cell monolayers and equine nasal mucosal explants.
- Author
-
Glorieux S, Vandekerckhove AP, Goris N, Yang XY, Steukers L, Van de Walle GR, Croubels S, Neyts J, and Nauwynck HJ
- Subjects
- Animals, Cell Line, Drug Evaluation, Preclinical, Guanine pharmacology, Herpesviridae Infections drug therapy, Herpesviridae Infections virology, Herpesvirus 1, Equid physiology, Horse Diseases virology, Horses, In Vitro Techniques, Nasal Mucosa virology, Virus Replication drug effects, Antiviral Agents pharmacology, Guanine analogs & derivatives, Herpesviridae Infections veterinary, Herpesvirus 1, Equid drug effects, Horse Diseases drug therapy
- Abstract
Equine herpesvirus 1 (EHV1) is a ubiquitous equine alphaherpesvirus that causes respiratory disease, neurological symptoms and abortions. Current vaccines are not fully protective and effective therapeutics are lacking. A-5021 [(1'S,2'R)-9-[[1',2'-bis(hydroxymethyl)cycloprop-1'-yl]methyl]guanine], previously shown to possess potent anti-herpetic activity against most human herpesviruses, was evaluated for its potential to inhibit EHV1 replication. In equine embryonic lung (EEL) cells, infected with either a non-neurovirulent (97P70) or a neurovirulent (03P37) EHV1 isolate, A-5021 proved to be about 15-fold more potent than acyclovir in inhibiting viral replication. Moreover, in equine nasal mucosal explants, A-5021 (at 8 and 32μM) was able to completely inhibit viral plaque formation whereas acyclovir did not exert an antiviral effect at these concentrations. Our data demonstrate that A-5021 is a potent inhibitor of EHV1 replication and may have potential for the treatment and/or prophylaxis of infections with this virus., (Copyright © 2011 Elsevier B.V. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF